"Switzerland Pharmaceuticals & Healthcare Report Q4 2014" now available at Fast Market Research

Most of Switzerland's demographic and economic indicators are favourable towards increased pharmaceutical and healthcare spending. The proportion of the pensionable population is high and growing, and this will translate into greater demand for drugs. Furthermore, the country's highly developed infrastructure means that access to healthcare is easy, further supporting the consumption of medicines.

Headline Expenditure Projections

* Pharmaceuticals: CHF7.06bn (USD7.68bn) in 2013 to CHF7.02bn (USD7.34bn) in 2014; -0.63% in local currency terms and -4.4% in US dollar terms.
* Healthcare: CHF68.18bn (USD74.11bn) in 2013 to CHF69.45bn (USD72.61bn) in 2014; +1.9% growth in local currency terms and -2.0% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/888515_switzerland_pharmaceuticals_healthcare_report_q4.aspx?afid=301

Risk/Reward Ratings: In BMI's Q414 Risk/Reward Ratings (RRRs) for Western Europe, Switzerland stands in second position in the Western Europe matrix. Switzerland's score for the quarter is 72.43, well above the regional average of 67.7.

Key Trends And Developments

In volume terms, Switzerland's pharmaceutical market experienced growth of 1.0% in 2013, with the number of medicines packs increasing to 209.8mn units. However, in value terms, the pharmaceutical market experienced a downturn in 2013 - declining by 0.3% in consumer price terms (a 0.1% decline in ex-factory price terms) to CHF7.06bn (USD7.68bn).

Multinational drugmaker Novartis posted a 2% increase in sales in US dollar terms (2% in constant currency terms) to USD14.64bn in Q214, up from USD14.35bn in Q213 - excluding divested blood transfusion diagnostics unit sales.

BMI Economic View: The Swiss economy will remain one of the stronger performers among developed states over the medium term, but will still be adversely affected by weak demand in the euro area. Moreover, despite domestic demand hitting a soft patch in the first quarter of 2014, we are sticking with our theme of longer-term rebalancing, which will be underpinned by favourable labour market dynamics and healthy...

The Switzerland Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Switzerland Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Swiss pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Switzerland to test other views - a key input for successful budgeting and strategic business planning in the Swiss pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Greece Pharmaceuticals & Healthcare Report Q4 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014